About 0.7% of the global population has active epilepsy, which translates to roughly 50 million people worldwide. That makes epilepsy one of the most common neurological conditions on the planet. But that snapshot number only tells part of the story. Your cumulative risk of developing epilepsy at some point in your life is significantly higher: about 3% by age 80.
Global Prevalence vs. Lifetime Risk
The 0.7% figure represents people living with active epilepsy at any given time, based on 2021 global data published in The Lancet Public Health. Of that total, about 0.3% have epilepsy with no identifiable underlying cause, while 0.4% have epilepsy linked to a known trigger like stroke, brain injury, or infection.
Lifetime risk paints a different picture. A study in Neurology calculated the cumulative probability of developing epilepsy at different ages: 0.9% by age 20, 1.6% by age 50, and 3.0% by age 80. The gap between prevalence and lifetime risk exists because many people develop epilepsy, get it under control or go into remission, and are no longer counted as “active” cases. Others develop it late in life and live with it for a shorter period.
U.S. Numbers
In the United States, about 2.9 million adults and 456,000 children have active epilepsy, according to CDC data from 2021 and 2022. That works out to roughly 1% of all U.S. adults, slightly higher than the global average. The higher figure likely reflects better diagnosis rates and longer life expectancy, since epilepsy incidence rises sharply in older adults after strokes and other age-related brain changes.
Who Gets Epilepsy More Often
Men carry a higher burden of epilepsy than women across every income level and world region. A large analysis of global data from 1990 to 2017 found that men had significantly higher prevalence rates than women in all socioeconomic groups. The disparity shows up not just in raw numbers but in the overall health impact: men lost about 208 disability-adjusted life years per 100,000 people compared to 184 per 100,000 for women in 2017. The reasons aren’t fully settled, but men face higher rates of head trauma and certain infections that can trigger epilepsy.
Age also matters. New cases of epilepsy follow a U-shaped curve, peaking in early childhood and again after age 60. In young children, the causes tend to be genetic or developmental. In older adults, stroke and neurodegenerative disease are the primary drivers.
What Causes It
More than half of all epilepsy cases, roughly 54% to 65%, have no identifiable cause. For the rest, the breakdown based on community studies looks like this:
- Stroke and other cerebrovascular disease: 11% to 21% of cases
- Brain tumors: 4% to 7%
- Head trauma: 2% to 6%
- Infections: up to 3%
These proportions shift depending on where you live. In lower-income countries, infections like neurocysticercosis (caused by a parasite) and complications during birth account for a larger share. In higher-income countries, stroke dominates as the leading identifiable cause, especially among older adults.
How Many People Respond to Treatment
About two-thirds of people with epilepsy can control their seizures with medication. The remaining third, roughly 33%, have what’s called drug-resistant epilepsy, meaning seizures persist despite trying appropriate treatments. That percentage isn’t uniform. It varies depending on the type of epilepsy, what caused it, how early seizures started, and whether other neurological conditions are present. People with drug-resistant epilepsy may be candidates for surgery, nerve stimulation devices, or specialized diets.
The Financial Weight
Epilepsy carries a substantial economic cost beyond its medical impact. In the U.S., average annual healthcare spending for a person with epilepsy is about $11,333, based on CDC data covering 2010 to 2018. Compared to people without the condition, those with epilepsy spend roughly $4,580 to $6,850 more per year on direct medical care after adjusting for other health and demographic factors. Those costs include medications, specialist visits, emergency care for breakthrough seizures, and in some cases, surgical evaluation. For the roughly one-third whose seizures don’t respond well to medication, costs tend to be even higher.